Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $795000.0.

  • Stoke Therapeutics' Other Accumulated Expenses rose 3316.58% to $795000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $795000.0, marking a year-over-year increase of 3316.58%. This contributed to the annual value of $753000.0 for FY2024, which is 1213.54% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Other Accumulated Expenses is $795000.0, which was up 3316.58% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Other Accumulated Expenses ranged from a high of $2.1 million in Q1 2025 and a low of $426000.0 during Q3 2022
  • Over the past 4 years, Stoke Therapeutics' median Other Accumulated Expenses value was $750000.0 (recorded in 2022), while the average stood at $848800.0.
  • As far as peak fluctuations go, Stoke Therapeutics' Other Accumulated Expenses crashed by 1213.54% in 2024, and later surged by 11163.27% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Other Accumulated Expenses (Quarter) stood at $509000.0 in 2022, then soared by 68.37% to $857000.0 in 2023, then decreased by 12.14% to $753000.0 in 2024, then grew by 5.58% to $795000.0 in 2025.
  • Its Other Accumulated Expenses was $795000.0 in Q3 2025, compared to $1.8 million in Q2 2025 and $2.1 million in Q1 2025.